Literature DB >> 35586442

Novel Quinoline Compounds as EZH2 Inhibitors for Treating Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35586442      PMCID： PMC9109473          DOI： 10.1021/acsmedchemlett.2c00139

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.

Authors:  Shanshan Sun; Feng Yu; Danying Xu; Haiyan Zheng; Min Li
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2022-02-22       Impact factor: 10.680

Review 2.  Role of EZH2 in bone marrow mesenchymal stem cells and immune-cancer interactions.

Authors:  Zhaoyun Liu; Yue Jia; Yixuan Guo; Hao Wang; Rong Fu
Journal:  Crit Rev Oncol Hematol       Date:  2021-11-26       Impact factor: 6.312

Review 3.  Non-coding RNAs-EZH2 regulatory mechanisms in cervical cancer: The current state of knowledge.

Authors:  Jianhong Zheng; Linlin Chen
Journal:  Biomed Pharmacother       Date:  2021-12-13       Impact factor: 6.529

Review 4.  Critical role of the high mobility group A proteins in hematological malignancies.

Authors:  Marco De Martino; Francesco Esposito; Alfredo Fusco
Journal:  Hematol Oncol       Date:  2021-10-12       Impact factor: 4.850

Review 5.  Epigenetic regulation in medulloblastoma pathogenesis revealed by genetically engineered mouse models.

Authors:  Ryo Shiraishi; Daisuke Kawauchi
Journal:  Cancer Sci       Date:  2021-05-29       Impact factor: 6.716

Review 6.  New insights into the interplay between long non-coding RNAs and RNA-binding proteins in cancer.

Authors:  Zi-Ting Yao; Yan-Ming Yang; Miao-Miao Sun; Yan He; Long Liao; Kui-Sheng Chen; Bin Li
Journal:  Cancer Commun (Lond)       Date:  2022-01-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.